Literature DB >> 1653103

Antiviral activity against transmissible gastroenteritis virus, and cytotoxicity, of natural porcine interferons alpha and beta.

H M Weingartl1, J B Derbyshire.   

Abstract

Porcine interferon (POIFN)-alpha prepared in primed peripheral blood leukocyte cultures induced with Newcastle disease virus and POIFN-beta from PK-15 cell cultures induced with polyinosinic:polycytidylic acid were partially purified by precipitation with potassium thiocyanate and anion exchange chromatography. Mean purification factors in terms of units of POIFN per mg of protein, of 37 and 12 were obtained for POIFN-alpha and POIFN-beta respectively. In yield reduction assays in swine testis and pig kidney cell cultures, POIFN-alpha and POIFN-beta had greater antiviral activity against vesicular stomatitis virus than against transmissible gastroenteritis virus (TGEV). The antiviral effects were greater at higher concentrations of interferon (IFN), and when the IFN treatments were continued postinfection. Porcine interferon-beta showed greater antiviral activity against TGEV than POIFN-alpha, but this may have been partly due to cytotoxicity. There were no major differences in the antiviral activities of crude and partially purified IFN preparations. Both types of IFN showed antiviral activity against TGEV in yield reduction assays in porcine intestinal explant and intestinal epithelial cell cultures. Crude POIFN-beta was found to be rapidly cytotoxic, especially in porcine cells, and some fractions of partially purified POIFN-beta were also cytotoxic. The cytotoxicity of POIFN-beta was partially neutralized by antibodies against human IFN-beta, but human IFN-beta was not cytotoxic for porcine or bovine cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653103      PMCID: PMC1263434     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  21 in total

1.  Induction of alpha interferon by transmissible gastroenteritis coronavirus: role of transmembrane glycoprotein E1.

Authors:  B Charley; H Laude
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Interferon induction with polyinosinic:polycytidylic acid in the newborn piglet.

Authors:  K G Loewen; J B Derbyshire
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

3.  A convenient and rapid cytopathic effect inhibition assay for interferon.

Authors:  P C Familletti; S Rubinstein; S Pestka
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  Porcine leukocyte interferon and antiviral activity in human cells.

Authors:  W A Carter; L R Davis; K C Chadha; F H Johnson
Journal:  Mol Pharmacol       Date:  1979-05       Impact factor: 4.436

5.  The interferon sensitivity of selected porcine viruses.

Authors:  J B Derbyshire
Journal:  Can J Vet Res       Date:  1989-01       Impact factor: 1.310

6.  Properties of natural porcine interferons.

Authors:  E Piasecki
Journal:  J Interferon Res       Date:  1988-02

7.  The effect of interferon induction in parturient sows and newborn piglets on resistance to transmissible gastroenteritis.

Authors:  K G Loewen; J B Derbyshire
Journal:  Can J Vet Res       Date:  1988-01       Impact factor: 1.310

8.  Effect of recombinant DNA-derived bovine alpha-1 interferon on transmissible gastroenteritis virus infection in swine.

Authors:  N J MacLachlan; K P Anderson
Journal:  Am J Vet Res       Date:  1986-05       Impact factor: 1.156

9.  The induction and characterization of natural porcine interferons alpha and beta.

Authors:  H M Weingartl; J B Derbyshire
Journal:  Can J Vet Res       Date:  1990-06       Impact factor: 1.310

10.  Cytocidal effect of interferons on porcine renal cells.

Authors:  H Laude; C La Bonnardiere
Journal:  J Interferon Res       Date:  1984
View more
  9 in total

1.  Receptor usage and cell entry of porcine epidemic diarrhea coronavirus.

Authors:  Chang Liu; Jian Tang; Yuanmei Ma; Xueya Liang; Yang Yang; Guiqing Peng; Qianqian Qi; Shibo Jiang; Jianrong Li; Lanying Du; Fang Li
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

Review 2.  Development of antiviral therapy for severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Gerold Hoever; Wolfgang Preiser; Hans Wilhelm Doerr
Journal:  Antiviral Res       Date:  2005-04-26       Impact factor: 5.970

3.  Transmissible gastroenteritis virus does not suppress IFN-β induction but is sensitive to IFN in IPEC-J2 cells.

Authors:  Liqi Zhu; Xing Yang; Chunxiao Mou; Qian Yang
Journal:  Vet Microbiol       Date:  2016-12-21       Impact factor: 3.293

4.  Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.

Authors:  Emily L C Tan; Eng Eong Ooi; Chin-Yo Lin; Hwee Cheng Tan; Ai Ee Ling; Bing Lim; Lawrence W Stanton
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

5.  Antiviral Activity of Porcine Interferon Regulatory Factor 1 against Swine Viruses in Cell Culture.

Authors:  Yongtao Li; Hongtao Chang; Xia Yang; Yongxiang Zhao; Lu Chen; Xinwei Wang; Hongying Liu; Chuanqing Wang; Jun Zhao
Journal:  Viruses       Date:  2015-11-17       Impact factor: 5.048

6.  Interferon induction in porcine leukocytes with transmissible gastroenteritis virus.

Authors:  D Naidoo; J B Derbyshire
Journal:  Vet Microbiol       Date:  1992-03       Impact factor: 3.293

7.  Antiviral activity of interferon against transmissible gastroenteritis virus in cell culture and ligated intestinal segments in neonatal pigs.

Authors:  L T Jordan; J B Derbyshire
Journal:  Vet Microbiol       Date:  1994-01       Impact factor: 3.293

Review 8.  Role of interferons in the treatment of severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Martin Scholz; Hans Wilhelm Doerr
Journal:  Expert Opin Biol Ther       Date:  2004-06       Impact factor: 4.388

9.  Antiviral action of interferon-alpha against porcine transmissible gastroenteritis virus.

Authors:  L T Jordan; J B Derbyshire
Journal:  Vet Microbiol       Date:  1995-06       Impact factor: 3.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.